Get all premium features to the best stock analysis tool

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel (amsoki-cel, formerly OBX-115), an engineered TIL cell therapy armored with pharmacologi.